Roberto Iacovelli, Medical Oncologist at Gemelli Polyclinic Foundation IRCCS, and Associate Professor of Medical Oncology at Catholic University, Comprehensive Cancer Center of Rome, Italy, shared on X:
“Proud to report at ESMO 2026 the results of PE-PE trial.
Oligometastatic RCC pts have a significant benefit when pembro was added to MDT irrespectively of the type of MDT used and up to 5y from previous surgery.
Thanks to the team and special thanks to Toni Choueiri.”
You can also read:
RAMPART at ESMO 2026: Patient-Reported Outcomes With Adjuvant Durvalumab in Resected RCC
